News

The Motley Fool1mon
Every Rivian Investor Should Keep an Eye on These 2 Numbers
Rivian stock has big upside potential. There are two numbers that investors must monitor. As you can see in the charts below, Rivian shares now trade at just 2.2 times sales -- a considerable ...
The Raw Story1mon
'Major red flag': Trump's two 'greatest assets' are reportedly 'becoming liabilities'
Travis Gettys is a senior editor for Raw Story based in northern Kentucky. He previously worked as a web editor for WLWT-TV and a contributing writer for the Kentucky Enquirer, and he also wrote ...
The Washington Post1mon
Trumpian math: Two nonsense numbers that don’t add up
Trump is peddling two nonsense numbers. First, that tariffs are already bringing in $3 billion a day. He’s off by a factor of 10. Second, that Biden was losing $2 billion a day. That reflects a ...
TechCrunch1mon
Apple says zero-day bugs exploited against ‘specific targeted individuals’ using iOS
Apple has released new software updates across its product line to fix two security vulnerabilities, which the company said may have been actively used to hack customers running its mobile ...
Newsweek1mon
How Many Migrants Has Trump Deported? White House Announces New Numbers
I suppose if the administration is claiming that they have done more than a third of that already in two ... deport using the CBP Home app, bypassing ICE enforcement. Again, exact numbers have ...
Australian Broadcasting Corporation5mon
International student numbers to be limited using legal workaround
The new directive is a workaround after the government failed to pass laws to cap student numbers through parliament ... Photo shows A graphic of two women in graduation outfits, against a ...
Finanznachrichten6mon
Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary ...
Nasdaq6mon
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed ...
Yahoo Finance6mon
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary ...
Yahoo Finance6mon
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of ...
Financial Post6mon
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...